What is MND SMART?
MND SMART (Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial) is 'multi-arm' meaning more than one treatment will be tested at the same time. In the first instance the trial will have 3 arms; drug 1 (Memantine Hydrochloride - phase 2), drug 2 (Trazodone Hydrochloride - phase 3) and placebo (dummy drug). This allows the evaluation of drug 1 versus placebo and separately drug 2 versus placebo. Participants will be randomly allocated to either drug 1, drug 2 or placebo. Medicines being tested are already approved for use in other conditions. Currently recruiting in trial centres across the UK.
New drugs will be selected for investigation in MND-SMART based on continuous review of constantly updated scientific evidence as well as findings from state-of-the-art human stem cell based drug discovery platforms.
For more information, you can see our take part in research webpage.
What do the drugs do?
Memantine hydrochloride is a drug which is already used to treat Alzheimer’s disease. It works by reducing the action of glutamate. Glutamate is a neurotransmitter, meaning it helps nerve cells to communicate. However, in MND it is thought that the over activity of glutamate can be toxic and cause cells to die.
Trazodone Hydrochloride is a drug which is already used to treat anxiety and depression. It works by slowing the production of faulty proteins in nerve cells. The accumulation of these faulty proteins is though to cause cells to die in MND.
The trial is currently recruiting in the UK and Republic of Ireland at the following sites:
- St George's London
- West Suffolk
- Ipswich, Norfolk
April 2022 - An independent review concluded that testing for both current drugs (Memantine and Trazodone) should be continued. Find out more here.
Jan 2022 - Over 260 participants have been recruited from 16 sites across the UK.
Last updated: 01/08/2022